Maturity

PR is an essential part of a biotechnology company's business strategy, but must be applied with caution.

Data management solutions are being tailored to the specific demands of large and small companies alike.

Biotechnology companies have several options when it comes to alleviating the “sting” of failing to get a lead product to market.

Strategies used by the pharmaceutical industry to alleviate the pain of patent expiration provide some valuable lessons for the biotechnology sector. . .and also some cautionary tales.

Biotechnology companies face an elusive threat—how to handle what they know.